For research use only. Not for therapeutic Use.
SPT-IN-1 (compound 1) is an orally active and potent SPT (serine palmitoyl transferase) inhibitor, with an IC50 of 5.19 nM for hSPT1. SPT-IN-1 can be used for type 2 diabetes and dyslipidemia research[1].
SPT-IN-1 (compound 1) exhibits a dose-dependent inhibition of C14-serine incorporation into ceramide in MCF-7 cells, with EC50 of 0.98 μM[1].
SPT-IN-1 (compound 1) (Sprague Dawley rats, 0-60 mg/kg, Orally, twice daily for 7 days) dose-dependently reduces plasma ceramides, reduces triglycerides and raises HDL in cholesterol/cholic acid fed rats[1].
CAS Number | 1933533-18-6 |
Synonyms | 2-[4-(6-heptanoylimidazo[1,2-a]pyridin-8-yl)phenyl]acetic acid |
Molecular Formula | C22H24N2O3 |
Purity | ≥95% |
InChI | InChI=1S/C22H24N2O3/c1-2-3-4-5-6-20(25)18-14-19(22-23-11-12-24(22)15-18)17-9-7-16(8-10-17)13-21(26)27/h7-12,14-15H,2-6,13H2,1H3,(H,26,27) |
InChIKey | MMYRYMMKMUTPBB-UHFFFAOYSA-N |
SMILES | CCCCCCC(=O)C1=CN2C=CN=C2C(=C1)C3=CC=C(C=C3)CC(=O)O |
Reference | [1]. Genin MJ, et al. Imidazopyridine and Pyrazolopiperidine Derivatives as Novel Inhibitors of Serine Palmitoyl Transferase. J Med Chem. 2016;59(12):5904-5910. |